One of our mantras at Madrona is “day one for the long run,” and our relationship with Archon Biosciences epitomizes this philosophy. We originally met James Lazarovits and George Ueda (both translational investigators in the Baker Lab at the Institute for Protein Design, University of Washington) at a dinner well over a year before the company was formally founded. They blew us away with their vision, scientific brilliance, and determination to build a long-term biotech company, and we spent the ensuing year working closely in anticipation of launching a product-focused company. We couldn’t be more excited to lead this round as they come out of stealth! https://lnkd.in/gtMEAgwD
Today, Archon Biosciences announced $20 million in seed financing led by Madrona and shared our vision for the future of drug development! We’ve built a completely novel class of biologics, Antibody Cages (AbCs) designed to unlock powerful therapeutic targets beyond the reach of existing modalities and to better treat disease. AbCs integrate the unparalleled binding properties of antibodies into a boundless set of AI-generated nanostructures that have never existed in nature. Precise control over AbC structures provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold standard for biologic medicines. Learn more in our press release here: https://lnkd.in/eTJxYNuk To see AbCs in action and learn more about how Archon is applying generative protein design to improve human health, visit our website at https://www.archon.bio/ #biotech #antibodies #AI #ComputationalProteinDesign #AbC